New Pharma Plant Opens in Nizwa: A Major Boost for Oman’s Drug Security and Investment Opportunities
Muscat: The Sultanate of Oman has taken a major step in enhancing national health security with the inauguration of the Izz Pharmaceuticals factory in Nizwa Industrial City. This facility is set to advance local pharmaceutical manufacturing and reduce dependence on imported medicines.
The factory was officially opened on Wednesday by Sultan bin Salim al Habsi, Minister of Finance, with Dr. Hilal bin Ali al Sabti, Minister of Health, along with senior officials and key stakeholders in attendance.
The event highlights Oman’s strategic initiative to localise crucial industries in alignment with Oman Vision 2040, particularly in sectors related to supply chain resilience and public health preparedness. Situated in Al Dakhiliyah Governorate, the factory incorporates advanced production technologies and quality control systems that adhere to international pharmaceutical standards.
Saif bin Khalfan al Hasani, CEO of Izz Pharmaceuticals, explained that selecting Nizwa for the facility was both symbolic and strategic. “Nizwa represents a city deeply rooted in Oman’s heritage while embracing a forward-thinking vision for industrial development,” he said.
Al Hasani noted that the project was conceived during the global disruptions caused by the Covid-19 pandemic, which revealed weaknesses in international medical supply chains. “Pharmaceutical security is no longer optional; it is a national imperative. This facility directly addresses that need by promoting self-sufficiency and protecting public health,” he added.
He further stressed that the factory underscores a commitment to balanced regional development. “Establishing this complex in Nizwa signals that industrial growth extends beyond major urban centers. It generates high-quality jobs and fosters inclusive economic growth across various governorates,” Al Hasani remarked.
The CEO emphasized adherence to rigorous quality and safety standards, alongside significant investment in cutting-edge technologies and human capital. “Our goal extends beyond production capacity to building public trust in Omani pharmaceutical products and contributing meaningfully to national objectives under Oman Vision 2040,” he said.
From the broader industry perspective, Balqees bint Saud al Makhmari, Director of the Investment Empowerment Department at the Ministry of Health, highlighted the rapid expansion of Oman’s medical manufacturing sector. “The industry is growing fast, with 20 operational pharmaceutical and medical factories producing over 2,000 products, and 18 more facilities currently under construction,” she revealed.
Al Makhmari pointed out that Omani pharmaceutical products are reaching over 32 international markets, reinforcing Oman’s emerging status as a regional medical manufacturing hub and a credible global supply chain player.
She emphasized that these advancements align closely with national economic diversification goals. “The Ministry of Health plays a crucial role in fostering investment through supportive regulations, strengthening public-private partnerships, and encouraging industrial growth in this vital sector,” she stated.
Al Makhmari also highlighted the importance of an efficient medical supply system. “Enhancing centralised procurement, improving inventory management, and ensuring cost efficiency are vital for maintaining healthcare services and readiness under all circumstances,” she added.
Covering approximately 20,000 square meters, the Izz Pharmaceuticals complex boasts state-of-the-art production lines and laboratories. The facility has an annual production capacity exceeding 18 million intravenous solution units, enabling it to satisfy a significant portion of domestic demand.
Industry experts note that intravenous solutions are among the most critical medical supplies, especially during emergencies and large-scale healthcare responses. Thus, this factory is expected to play a pivotal role in stabilising supply chains and ensuring consistent availability across Omani healthcare institutions.
Besides production, the project aims to foster innovation and workforce development by offering specialised employment opportunities for Omani professionals in pharmaceutical manufacturing, technical operations, and management. This supports broader Omanisation efforts in high-value industries.
The factory is also expected to substantially reduce Oman’s pharmaceutical import bill and bolster resilience against external supply disruptions. It opens opportunities for future expansion into regional and international markets by leveraging the country’s growing industrial capabilities.
The inauguration of Izz Pharmaceuticals marks a significant move towards industrial self-reliance, merging economic diversification with human capital advancement. As production begins, the facility strengthens confidence in locally made medicines and positions Oman to compete more effectively on the global pharmaceutical stage.
Special Analysis by Omanet | Navigate Oman’s Market
The launch of Izz Pharmaceuticals in Nizwa marks a transformative milestone for Oman’s healthcare and industrial sectors, significantly reducing dependency on imports and enhancing national pharmaceutical self-sufficiency. For businesses and investors, this signals a strategic opportunity to engage in a rapidly expanding medical manufacturing ecosystem supported by Vision 2040’s diversification goals. Smart entrepreneurs should prioritize innovation, quality standards, and workforce development to capitalize on Oman’s growing role as a regional pharmaceutical hub while mitigating risks tied to global supply chain disruptions.
